Compare EVR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVR | BMRN |
|---|---|---|
| Founded | 1995 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 10.5B |
| IPO Year | 2006 | 1999 |
| Metric | EVR | BMRN |
|---|---|---|
| Price | $332.15 | $53.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 19 |
| Target Price | ★ $320.11 | $88.42 |
| AVG Volume (30 Days) | 344.0K | ★ 3.0M |
| Earning Date | 10-29-2025 | 10-27-2025 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ 61.11 | 59.53 |
| EPS | ★ 12.55 | 2.68 |
| Revenue | ★ $3,542,875,000.00 | $3,094,001,000.00 |
| Revenue This Year | $25.39 | $13.39 |
| Revenue Next Year | $16.43 | $7.57 |
| P/E Ratio | $26.43 | ★ $19.92 |
| Revenue Growth | ★ 27.03 | 12.39 |
| 52 Week Low | $148.63 | $50.76 |
| 52 Week High | $364.42 | $73.51 |
| Indicator | EVR | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 62.83 | 46.19 |
| Support Level | $310.93 | $53.03 |
| Resistance Level | $322.82 | $54.66 |
| Average True Range (ATR) | 11.11 | 1.45 |
| MACD | 3.21 | -0.11 |
| Stochastic Oscillator | 87.16 | 31.61 |
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.